Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response of Low-dose IL-2 (ILT-101) in Healthy Volunteers
NCT03837093Phase 1Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2019
- Primary completion
- Mar 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised trial of aldesleukin in autoimmune diseases (6 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Variation of Regulatory T-cells. Started Jun 2019; status: completed.
02
Drugs
aldesleukin
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT03837093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03837093.